In a post on the the IVI-sponsored Health Affairs blog series, Peter Neumann and co-author Elle Pope examine Section 3037 of the Cures Act and new FDA draft guidance, which indicate that drug companies will have expanded flexibility to communicate proactively with payers and formulary committees about the real-world impacts of their products.
Read the full article here.
About the Health Affairs/IVI Blog Series: Drugs and Medical Innovation — In partnership with Health Affairs, IVI is proud to sponsor the “Drugs and Medical Innovation” blog series. On an ongoing basis, articles in this series will explore topics such as value-based reimbursement, drug policy and pricing, balancing short-term access against long-term rates of innovation, and other relevant issues. Our goal is to create an open forum for sharing ideas and debating issues in these areas, extending the discussion to a broader audience.